RxDoctor Payments Data

Michail Vitellas, MD

Cardiovascular Disease · Johnson City, NYNPI 1023252293

Payments from drug & device makers

$5,118in general payments, 2019–2025

Across 147 payments — averaging $34.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$600
  • Edwards Lifesciences$549
  • Abiomed$317
  • Medtronic$257
  • Amgen$119
  • plus $781 from 16 others

What the payments were for

  • Travel & lodging$99920%
  • Food & beverage$4,12080%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,118 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$166,797
Medicare patients
1,602
Services billed
3,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$169,705
EntrestoSacubitril/Valsartan89$100,244
EliquisApixaban50$69,818
BrilintaTicagrelor22$25,652
Metoprolol Succinate122$2,261
Mexiletine Hcl13$2,147
Rosuvastatin Calcium111$1,596
Amiodarone Hcl57$1,253
Ezetimibe32$973
Atorvastatin Calcium74$895
ClopidogrelClopidogrel Bisulfate67$810
Digoxin16$698
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$550
Carvedilol51$545
Enalapril Maleate14$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$56$169,705108 claims
NovartisEntresto$600$100,24489 claims
PfizerEliquis$114$69,81850 claims
AstraZenecaBrilinta$15$25,65222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →